Navigation Links
Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
Date:5/17/2013

Atlanta, GA (PRWEB) May 17, 2013

Dr. Sparano is Professor of Medicine and Professor of Obstetrics, Gynecology, and Women’s Health at the Albert Einstein College of Medicine and Associate Chairman of the Department of Oncology at the Montefiore Medical Center. He is also Associate Director for Clinical Research at the Einstein Cancer Center and leads the Einstein Breast Cancer Working Group, a multidisciplinary group of physicians and scientists focused on translational breast cancer research. He also serves as Vice Chair of the National Cancer Institute Breast Cancer Correlative Science Committee and Vice Chair of the AIDS Malignancy Consortium.

The Albert Einstein College of Medicine and Montefiore Medical Center have been members of ECOG since 1978.

Dr. Sparano is a medical oncologist whose research focuses on developmental therapeutic approaches in breast cancer, lymphoma, and HIV-associated cancers and the clinical application of genomic profiling in cancer management. He first joined ECOG in 1991 as a member of the Biological Response Modifier Committee and Breast Committee. Dr. Sparano has held the position of Co-Chair or Chair of the ECOG Breast Committee since 2002 and Associate Chair for Disease and Modality Research since 2001. He has chaired or co-chaired 16 therapeutic clinical trials for the Group, including the historic Trial Assigning IndividuaLized Options for Treatment (Rx) (or TAILORx)—an ongoing study in women with early stage breast cancer, whose results, when they become available, will help to identify those for whom adjuvant hormonal therapy alone is sufficient, thus potentially eliminating the empiric use of chemotherapy in tens of thousands of such women each year.

Dr. Sparano has coauthored approximately 180 scientific publications, and this work includes establishing a role for weekly paclitaxel as adjuvant therapy in breast cancer, infusional therapy in lymphoma, biologic therapy in human papillomavirus (HPV)-associated cancer, and defining tumor and host determinants of breast cancer recurrence. He recently established a breast cancer biospecimen banking program that will serve as a resource to study biospecimens from women who have survived early stage breast cancer and to identify whether dormant tumor cells and their interaction with the microenvironment puts patients at risk for a recurrence of the disease later in life. The Breast Cancer Late Relapse Biorepository is funded by the Breast Cancer Research Foundation and the Susan G. Komen for the Cure Foundation.

The appointment was announced today at the Group’s semiannual scientific meeting in Atlanta.

About the ECOG-ACRIN Cancer Research Group
The ECOG-ACRIN Cancer Research Group is a member network that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. It was formed in May 2012 by the merger of the Eastern Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging Network (ACRIN), two highly respected National Cancer Institute (NCI)-sponsored cancer cooperative groups. The Group comprises nearly 650 member institutions, including community hospitals, academic medical centers, NCI-designated cancer centers, Community Cancer Oncology Programs (CCOPs) and Minority-based CCOPs, health systems, and physician practices, in the United States and around the world. Approximately 6000 individual physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research, which is organized into three programs: Cancer Control and Outcomes, Therapeutic Studies and Biomarker Sciences.

For more information, visit http://www.ecog-acrin.org.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10746679.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved


Related biology technology :

1. TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
2. Dr. Peter C. Neligan, Author of 3rd Edition of Elseviers Plastic Surgery Text, Available for Comment on the Contributions of Dr. Joseph Murray
3. St. Jude scientist named Howard Hughes Medical Institute investigator
4. CellHealth Institute is Named 2013 Edison Award Winner
5. Health Decisions CEO Michael Rosenberg Named a Business Leader Top Entrepreneur for 2013
6. Street Named After EMCO High Voltage Corporation
7. Serial Entrepreneur Ken Malone Named BHI Entrepreneur-in-Residence to Offer Commercialization Guidance to Start-Ups Based on UM Discoveries
8. Roberto DellOro Named Director of LMUs Bioethics Institute
9. Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus
10. Bright Cluster Manager Named Bio-IT World Conference "Best in Show" Finalist
11. Cambridge Semantics Named 2013 SIIA CODiE Award Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... 2014 BioMedomics, Inc. , a Point ... platforms and novel disease specific POC tests, announced today that ... a total of $690,000. The investment is from private investors ... This group of private investors has significant successful experience in ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... as soon as they,re planted may be good news for ... In the wild, a plant whose seeds sprouted at the ... than just an insurance policy against late frosts or unexpected ... advantages too: Plants whose seeds put off sprouting until ... in a team of researchers working at the National Evolutionary ...
(Date:4/17/2014)... A drug under clinical trials to treat tuberculosis ... drugs that act against various bacteria, fungal infections and ... University of Illinois chemists and collaborators. , Led by ... determined the different ways the drug SQ109 attacks the ... target other pathogens from yeast to malaria and ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2